Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study - Wikidata - wikimedia - TriplyDB

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

http://www.wikidata.org/entity/Q33996608

about

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results The design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agents Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer.New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.Targeting angiogenesis in metastatic breast cancer Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].New oral multitargeted antiangiogenics in non-small-cell lung cancer treatment.The potential of sunitinib as a therapy in ovarian cancer.Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors.Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles.Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.

P2860

Q26747666-C6FB720F-796B-4BAF-BE14-F37A6C839D48 Q33393174-D0B8EC87-9ABB-41F7-B9A9-99EEFE2CCABE Q33872751-D67FBEF9-8713-4A0E-BE72-70B3A0D3E831 Q34854658-98B4B8D2-E242-4FA2-B440-A95080B1B2A0 Q35660763-70801D85-D846-4B5C-821F-8399B290B4A4 Q35703904-DCC743EB-6278-4213-A144-707CDF6BE659 Q35927364-F4B0E7E6-69A4-4A2D-ACFA-2DFDE8DF3760 Q36182795-B314A224-ED77-401F-87DA-58FD0D0D854D Q37624187-5917D5D1-25D1-46BB-98A0-4DFF92B8E733 Q38014533-6D958BA7-4C3D-4824-A644-E5FB6DED7641 Q38144166-7A6F5B79-43B5-4DF3-99F6-731CCA67592D Q38552109-B7470E6E-8466-4757-9C5B-15B2F211BA02 Q39499521-DF79ED7F-A061-4A8C-856A-F70C17A878FA Q43841175-EA011F4A-8A2F-401E-B6D0-CA5CF04F61DF Q47957959-DBFC3278-1BED-45FC-B492-71B0057F1654 Q54563946-018BD418-553D-4F5E-B0F1-CF6CACF5B2CD

P2860

Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

http://www.wikidata.org/entity/Q33996608

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Sunitinib in combination with ...... phase I dose-escalation study

@ast

Sunitinib in combination with ...... phase I dose-escalation study

@en

type

label

Sunitinib in combination with ...... phase I dose-escalation study

@ast

Sunitinib in combination with ...... phase I dose-escalation study

@en

prefLabel

Sunitinib in combination with ...... phase I dose-escalation study

@ast

Sunitinib in combination with ...... phase I dose-escalation study

@en

P1433

Q33996608-C4E68B0D-5BC5-40CD-97DA-775A311ACAA4

P1476

Q33996608-F6A3D8BE-5EA4-478B-882E-3C8151594DB5

P2093

Q33996608-1C46DECF-64A4-4DBE-9EA8-2E394FE599CE

Q33996608-1DE1E710-9251-4A73-9F15-B57F8CB001AF

Q33996608-3C86B6C8-1D98-400B-8525-542F4D594DAB

Q33996608-45ABB1C3-AF77-4A38-8913-F86E39AEE946

Q33996608-4CC46E9A-922F-4A64-B820-F1173537944F

Q33996608-6C9E61D2-6CED-4155-A2E1-066C9AD56AA7

Q33996608-70E0AB30-7505-4487-BA3F-10348876B470

Q33996608-89FEBD29-CDC9-4B38-A94F-792E0522B854

Q33996608-AA753238-02C6-4A29-A715-540B1485A0EE

Q33996608-D9CA9184-B311-4D12-BD5B-C847A9ECEA8E

P2860

Q33996608-05E8E23F-B257-4DF0-80A3-81991E11987F

Q33996608-07E1C25B-A4FF-40FD-AEF3-F6DB04FDE557

Q33996608-18214FB5-9475-488E-AB59-47318223B6B4

Q33996608-18A3F9A7-08B8-48CA-B264-F0D20E809AF3

Q33996608-2482F8CE-D3C2-4854-B313-E1F1BD0ECE59

Q33996608-282BDD3B-02AC-44B8-A5D5-468FB9C40E2D

Q33996608-2A6A8B60-30DC-4DFA-8075-38B70A07EB2C

Q33996608-46E0A645-E42C-4D08-BB1C-DFA5DEF18F3B

Q33996608-50845C7F-658A-4DC0-8F71-9684C4B75CE4

Q33996608-5777AF70-442A-45F3-A7A7-0E8ECAF30EFA

P2888

Q33996608-B3F7A791-03A6-4930-8AC8-A3CBBF5BDDA5

P304

Q33996608-2D728DB4-32EC-4837-BE9B-7CCBBD48236F

P31

Q33996608-853610A7-F2CC-4111-903E-74F86ED2E654

P356

Q33996608-8B1EE636-F6DB-4DB8-AC71-B20B998C9EF3

P433

Q33996608-8D8E8EC8-AB91-4087-97DF-B3C7BF3FC30A

P478

Q33996608-FBF18E99-46F5-4D2A-A19A-2DD4BC5AA19F

P577

Q33996608-AE37933D-2F8A-4827-BA2D-23B6095344C4

P5875

Q33996608-AB194C1B-7E08-4283-8B92-2F343F643038

P6179

Q33996608-2B08C553-21B4-4E96-884A-5D8DD78FA4E2

P698

Q33996608-A0844077-BFF5-492F-A496-A51F5F183D73

P932

Q33996608-9F18320C-54EB-479E-9110-6D81F9301210

P356

S00280-009-1209-0

P1433

Cancer Chemotherapy and Pharmacology

P1476

Sunitinib in combination with ...... phase I dose-escalation study

@en

P2093

Alan Sandler

http://www.w3.org/2001/XMLSchema#string

Anne M Traynor

http://www.w3.org/2001/XMLSchema#string

Francisco Robert

http://www.w3.org/2001/XMLSchema#string

Glenn Liu

http://www.w3.org/2001/XMLSchema#string

Jennifer Ilagan

http://www.w3.org/2001/XMLSchema#string

Joan H Schiller

http://www.w3.org/2001/XMLSchema#string

Karen Harper

http://www.w3.org/2001/XMLSchema#string

Lesley Tye

http://www.w3.org/2001/XMLSchema#string

Lev Verkh

http://www.w3.org/2001/XMLSchema#string

Richard Chao

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.

Docetaxel for treatment of solid tumours: a systematic review of clinical data.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis.

Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review.

P2888

s00280-009-1209-0

P304

669-680

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00280-009-1209-0

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

66

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40820119

http://www.w3.org/2001/XMLSchema#string

P6179

1025389146

http://www.w3.org/2001/XMLSchema#string

P698

20043166

http://www.w3.org/2001/XMLSchema#string

P932

2904454

http://www.w3.org/2001/XMLSchema#string